Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Up-to-Date Always use the latest 2026 GL5197E (Mounjaro) form version
Retatrutide targets three hormone receptors simultaneously (GLP-1, GIP, and glucagon), distinguishing it from approved agents such as semaglutide (GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist)
In fact, in a 2017 review of five studies published in the journal Obesity Science & Practice , researchers determined that patients taking liraglutide lost at least 5 to 10 percent of their body weight as compared with those taking the placebo
The 2026 Regulatory Landscape The legal ground beneath compounded GLP-1 medications shifted significantly in late 2025 and early 2026
US$ 20.92
US$ 23.88
US$ 27.79
US$ 28.22
US$ 26.55
US$ 22.32
US$ 21.07
US$ 24.79
US$ 29.81
US$ 24.04
